Cogent Biosciences (COGT) Assets Average (2018 - 2026)

Cogent Biosciences' Assets Average history runs 9 years deep, the most recent figure standing at $920.3 million for Q1 2026.

• In Q1 2026, Assets Average rose 200.9% year-over-year to $920.3 million; the TTM figure through Mar 2026 stood at $920.3 million (up 200.9% YoY), while the FY2025 annual figure was $632.8 million, up 97.32% from the prior year.
• Assets Average was $920.3 million for Q1 2026 at Cogent Biosciences, up from $681.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $920.3 million in Q1 2026 to a low of $219.5 million in Q1 2022.
• Historically, Assets Average has averaged $390.4 million across 5 years, with a median of $348.8 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Assets Average tumbled 38.35% in 2025, then jumped 200.9% in 2026.
• A 5-year view of Assets Average shows it stood at $316.2 million in 2022, then rose by 5.77% to $334.4 million in 2023, then gained by 6.43% to $356.0 million in 2024, then surged by 91.53% to $681.8 million in 2025, then soared by 34.99% to $920.3 million in 2026.
• The last three Assets Average figures came in at $920.3 million (Q1 2026), $681.8 million (Q4 2025), and $350.4 million (Q3 2025), per Business Quant data.